

Q-linea enters the Middle East region through partnership with AMICO Group

Q-linea AB (publ) (OMX: QLINEA) today announces that the company is expanding into the Middle East through an exclusive agreement with AMICO Group

AMICO Group was founded by Akef El Maghraby M.D. & Mehran Hazarian in 1984. The company employs 1,300+ people with direct operations in 12 countries in the Middle East and North Africa, operating from 22 offices. The exclusive distribution agreement with Q-linea covers the GCC countries, including the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain and Oman.

Antimicrobial resistance (AMR) has significantly increased in the region over the past decade. The board members of the Gulf Cooperation Council Center for Infection Control (GCC-IC) developed a draft strategic plan for combating AMR in 2014. The final version was approved in 2016 and each GCC country moved on to develop and implement their respective plans.

Stuart Gander, CEO of Q-linea, said “One of the pillars of the action plans is to optimize use of antibiotics. Potential strategies include rapid diagnostics and the ability to optimize antibiotic dose, both of which the ASTar® System provides. The GCC countries represent a significant opportunity for growth in service to sepsis patients. We are confident that our partnership with AMICO Group will provide outstanding service and support to ASTar customers.”

Sherif Harydi, Business Development Director at AMICO Group, said “ We’re thrilled to announce that AMICO Group is making its mark combating sepsis and fighting AMR in the Middle East by partnering with Q-linea. This exclusive agreement will enable us to distribute the cutting-edge ASTar® System in the GCC countries, including the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman. Join us as we embark on this important journey to provide exceptional healthcare across the Middle East!”

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Q-linea enters the Middle East region through partnership with AMICO Group](#)